Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Merus NV MRUS

Healthcare Biotechnology
Merus NV is the Netherlands - based biotechnology company, concentrated on developing differentiating therapeutics for cancer patients. The product programs in the Merus pipeline are based on the Multiclonics format. Its products are designed to bind to multiple targets, and are manufactured with features for anti-cancer effects against the complex mechanisms that drive cancer. Company's... see more

Recent & Breaking News (NDAQ:MRUS)

Merus Announces First Patient Treated in Phase 1 Clinical Trial of MCLA-145 for Advanced Solid Tumors

Thomson Reuters ONE May 9, 2019

Merus Announces First Patient Treated in Phase 1 Clinical Trial of MCLA-145 for Advanced Solid Tumors

GlobeNewswire May 9, 2019

Merus Announces IND Clearance for MCLA-145

GlobeNewswire January 7, 2019

ProBioGen's GlymaxX® ADCC Enhancement Technology Used by Betta Pharmaceuticals

PR Newswire January 3, 2019

Merus Announces Strategic Collaboration with Betta Pharmaceuticals to Develop and Commercialize MCLA-129 in China

GlobeNewswire January 2, 2019

The Daily Biotech Pulse: Opko Settles With SEC, Obalon Inks Financing Deals, Harpoon Files For IPO

Benzinga.com  December 28, 2018

Merus Announces Financial Results for the Third Quarter 2018 and Provides Business Update

GlobeNewswire December 27, 2018

Merus Announces Global Settlement and End to All Patent Litigation with Regeneron Pharmaceuticals

GlobeNewswire December 20, 2018

Merus to Present at the Jefferies 2018 London Healthcare Conference

GlobeNewswire November 8, 2018

Merus to Present at the Cantor Fitzgerald Global Healthcare Conference

GlobeNewswire September 27, 2018

Merus Strengthens Team with Key Appointments

GlobeNewswire September 27, 2018

Merus to Participate in Citi’s 13th Annual Biotech Conference

GlobeNewswire August 30, 2018

Merus Announces Formation of a Scientific Advisory Board

GlobeNewswire August 22, 2018

Recent Analysis Shows DURECT, Corporacion America Airports S.A., Golden Star Resources, MacroGenics, Merus N.V., and Superior Uniform Group Market Influences — Renewed Outlook, Key Drivers of Growth

GlobeNewswire August 21, 2018

Merus Announces Financial Results for the Second Quarter 2018 & Mid-year Operating Results

GlobeNewswire August 10, 2018

Merus to Present at the 2018 Wedbush PacGrow Healthcare Conference

GlobeNewswire August 7, 2018

Merus Announces Recent Corporate Developments and Financial Results for the First Quarter 2018

GlobeNewswire July 26, 2018

Merus to Present at the Jefferies 2018 Healthcare Conference

GlobeNewswire May 31, 2018

Merus Announces First Patient Dosed in Phase 1 Clinical Trial of MCLA-158 in Patients with Solid Tumors

GlobeNewswire May 24, 2018

Merus Announces Unique Mechanism of Action of MCLA-128 That Potently Blocks HER3 Signaling Published in Cancer Cell

GlobeNewswire May 15, 2018